Heat Biologics Selects Adaptive Biotechnologies to Discover Potential Clinical Biomarkers to Advance Novel Immunotherapies
October 11 2016 - 7:30AM
Heat Biologics, Inc.
(Nasdaq:HTBX)
, announced that they have advanced
their biomarker discovery collaboration with Adaptive
Biotechnologies. Adaptive will use its patented immune
profiling assay, immunoSEQ™, to enable an in-depth characterization
of the immune response to Heat’s ImPACT and ComPACT-based
immunotherapies, including HS-410, Heat’s Phase 2 product candidate
for non-muscle invasive bladder cancer. The immunoSEQ Assay, when
used to evaluate the mechanism of action of the ImPACT platform,
provides a significant biomarker identification opportunity to
better select patients and accelerate future enrollment based on
immune status.
“Previously reported data using Adaptive’s
immunoSEQ Assay, demonstrated a trend between established
anti-tumor immune responses and clinical outcomes with HS-410,”
stated Taylor Schreiber, M.D., Ph.D., Heat’s Chief Scientific
Officer. “The Adaptive Assay allows us to quantify the clonality of
a T-cell response generated by our ImPACT platform. Future work
should continue to be fruitful as we advance our understanding of
the patients that benefit most from treatment.”
About Heat Biologics, Inc. Heat
Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company
developing novel therapies that activate a patient’s immune system
against cancer. Heat’s highly specific T cell-stimulating
platform technologies, ImPACT and ComPACT, form the basis of its
product candidates. These platforms, in combination with
other therapies, such as checkpoint inhibitors, are designed to
address three distinct but synergistic mechanisms of action: robust
activation of CD8+ “killer” T cells (one of the human immune
system’s most potent weapons against cancer); T cell co-stimulation
to further enhance patients’ immune response; and reversal of
tumor-induced immune suppression. Currently, Heat is
conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in
patients with non-muscle invasive bladder cancer (NMIBC) and a
Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination
with an anti-PD-1 checkpoint inhibitor to treat patients with
non-small cell lung cancer (NSCLC). For more information,
please visit www.heatbio.com.
Forward Looking Statements This
press release includes forward-looking statements on our current
expectations and projections about future events. In some cases
forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions. These statements are based upon current beliefs,
expectations and assumptions and include statements regarding the
potential for the exploration of immune response to identify
patient populations more likely to respond to Heat’s therapies,
These statements are subject to a number of risks and
uncertainties, many of which are difficult to predict, including
the ability of immunoSEQ™ and Heat's ImPACT and ComPACT therapies
to perform as designed, the ability to enroll patients and complete
the clinical trials on time, the other factors described in our
annual report on Form 10-K for the year ended December 31, 2015 and
Heat's other filings with the SEC. The information in this
release is provided only as of the date of this release, and we
undertake no obligation to update any forward-looking statements
contained in this release based on new information, future events,
or otherwise, except as required by law.
CONTACT:
For Investor Inquiries:
David Waldman
919-240-7133
Investorrelations@heatbio.com
For Media Inquiries:
Deanne Eagle
Planet Communications
917-837-5866
deanne@planetcommunications.nyc
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Apr 2023 to Apr 2024